Arcadia Biosciences, Inc. Cash Flow Statement
RKDA|11 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
Arcadia Biosciences, Inc. used $10M in operating cash flow and negative free cash flow of $10M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$7.0M | -$14.0M | -$15.4M | -$14.7M | -$4.7M | -$28.8M | -$13.5M | -$15.7M | -$19.6M | -$18.0M | -$18.3M |
| Depreciation & Amortization | $58.0K | $111.0K | $439.0K | $929.0K | $632.0K | $194.0K | $154.0K | $279.0K | $304.0K | $294.0K | $358.0K |
| Operating Cash Flow | -$9.6M | -$15.3M | -$14.0M | -$25.9M | -$30.2M | -$17.2M | -$13.6M | -$14.0M | -$17.1M | -$15.1M | -$14.8M |
| Capital Expenditures | $16.0K | $5.0K | $72.0K | $1.0M | $2.3M | $1.5M | $250.0K | $79.0K | $231.0K | $151.0K | $148.0K |
| Free Cash Flow | -$9.6M | -$15.3M | -$14.0M | -$26.9M | -$32.6M | -$18.7M | -$13.9M | -$14.0M | -$17.3M | -$15.3M | -$14.9M |
| FCF Margin | -191.1% | -343.5% | -189.4% | -396.4% | -405.2% | -1597.5% | -948.2% | -348.8% | -542.2% | -281.9% | -213.9% |